Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the ESMO Congress 2023 and the 2023 ASCO Annual Meeting, focusing on how these updates continue to shift clinical practice and advance care.
A plant failure soon after the launch of semaglutide, hailed a gamechanger for the treatment of obesity (Wegovy), led to a US shortage, a formal halt to new drug starts, and some creative workarounds.